Trial reportBMC psychology2026
Evaluation of the effectiveness of Reframe-IT + to prevent suicidal ideation and other mental health outcomes among adolescents in Chile: 3-month, 6-month and 10-month follow-up.
Trial report in BMC psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05229302 (Testing the Effectiveness of a CBT Online-based Program to Reduce Suicide Ideation Among School Adolescents in Chile), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testing the Effectiveness of a CBT Online-based Program to Reduce Suicide Ideation Among School Adolescents in Chile: A Cluster Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSchools are suitable settings to prevent suicide among adolescents. We tested the effectiveness of a school-based program to reduce suicidal ideation (SI) (Reframe-IT +). It encompasses 13 sessions (eight internet-based and five face-to-face sessions).
methodsWe conducted a cluster RCT among students aged 13-18. Twenty-one schools were randomized (Intervention Group (IG), N = 47); Control Group (CG), N = 48)). The primary outcome was SI. Secondary outcomes were depressive and anxiety symptoms, psychotic experiences, hopelessness, and emotion regulation strategies (cognitive reappraisal, and emotion suppression), problem-solving skills and behavioral activation. Outcomes were assessed at baseline, post-intervention, 3-month, 6-month, and 10-month follow-up).
trial registrationClinical Trials NCT05229302. Registered on Registered on February 8, 2022.
resultsWe found a non-significant overall intervention effect on SI across follow-up assessments, but significant overall intervention effects on depressive and anxiety symptoms and psychotic experiences. Moreover, we found time-specific reductions immediately after the intervention and close to it, particularly for depressive and anxiety symptoms, hopelessness, behavioral activation and cognitive re-appraisal. The change favoring the IG of cognitive re- appraisal was also significant at 10 months follow-up.
conclusionsOur results suggest that Reframe-IT + reduces depressive and anxiety symptoms and psychotic experiences in the long term. Less promising results were related to suicidal ideation prevention. Further research is needed with a larger sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.